YCLOAK

When a volcanic eruption buried the ancient city of Pompeii, the last desperate moments of its citizens were preserved in stone for centuries.

Observers see stories in the plaster casts later made of their bodies, like a mother holding a child and two women embracing as they died.

But new DNA evidence suggests things were not as they seem — and these prevailing interpretations come from looking at the ancient world through modern eyes.

“We were able to disprove or challenge some of the previous narratives built upon how these individuals were kind of found in relation to each other,” said Alissa Mittnik of the Max Planck Institute for Evolutionary Anthropology in Germany. “It opens up different interpretations for who these people might have been.”

Mittnik and her colleagues discovered that the person thought to be a mother was actually a man unrelated to the child. And at least one of the two people locked in an embrace — long assumed to be sisters or a mother and daughter — was a man. Their research was published Thursday in the journal Current Biology.

The team, which also includes scientists from Harvard University and the University of Florence in Italy, relied on genetic material preserved for nearly two millennia. After Mount Vesuvius erupted and destroyed the Roman city in 79 A.D., bodies buried in mud and ash eventually decomposed, leaving spaces where they used to be. Casts were created from the voids in the late 1800s.

Researchers focused on 14 casts undergoing restoration, extracting DNA from the fragmented skeletal remains that mixed with them. They hoped to determine the sex, ancestry and genetic relationships between the victims.

There were several surprises in “the house of the golden bracelet,” the dwelling where the assumed mother and child were found. The adult wore an intricate piece of jewelry, for which the house was named, reinforcing the impression that the victim was a woman. Nearby were the bodies of another adult and child thought to be the rest of their nuclear family.

DNA evidence showed the four were male and not related to one another, clearly showing “the story that was long spun around these individuals” was wrong, Mittnik said.

Researchers also confirmed Pompeii citizens came from diverse backgrounds but mainly descended from eastern Mediterranean immigrants – underscoring a broad pattern of movement and cultural exchange in the Roman Empire. Pompeii is located about 241 kilometers from Rome.

The study builds upon research from 2022 when scientists sequenced the genome of a Pompeii victim for the first time and confirmed the possibility of retrieving ancient DNA from the human remains that still exist.

“They have a better overview of what’s happening in Pompeii because they analyzed different samples,” said Gabriele Scorrano of the University of Rome Tor Vergata, a co-author of that research who was not involved in the current study. “We actually had one genome, one sample, one shot.”

Though much remains to be learned, Scorrano said, such genetic brushstrokes are slowly painting a truer picture of how people lived in the distant past. 
…

Federal health officials on Thursday called for more testing of employees on farms with bird flu after a new study showed that some dairy workers had signs of infection, even when they didn’t report feeling sick. 

Farmworkers in close contact with infected animals should be tested and offered treatment even if they show no symptoms, said Dr. Nirav Shah, principal director of the U.S. Centers for Disease Control and Prevention. 

The new guidance comes after blood tests for 115 farmworkers in Michigan and Colorado showed that eight workers — or 7% — had antibodies that indicated previous infection with the virus known as Type A H5N1 influenza. 

“The purpose of these actions is to keep workers safe, to limit the transmission of H5 to humans and to reduce the possibility of the virus changing,” Shah told reporters. 

The CDC study provides the largest window to date into how the bird virus first detected in March in dairy cows may be spreading to people. It suggests that the virus has infected more humans than the 46 farmworkers identified in the U.S. as of Thursday. Nearly all were in contact with infected dairy cows or infected poultry. 

Outside experts said it’s notable that the study prompted the CDC to take new action. Previous recommendations called for testing and treating workers only when they had symptoms. 

“This is a significant move towards the assessment that these H5N1 viruses are a greater risk than the CDC estimated before,” said Dr. Gregory Gray, an infectious disease researcher at the University of Texas Medical Branch in Galveston. 

Every additional infection in animals or humans gives the virus the chance to change in potentially dangerous ways, said Angela Rasmussen, a virus expert at the University of Saskatchewan in Canada. 

“It shows yet again that we are not responding effectively to the H5N1 cattle outbreak in humans or animals and if we continue to let this virus spread and jump from species to species, our luck will eventually run out,” Rasmussen said in an email. 

The CDC study included 45 workers in Michigan and 70 in Colorado tested between June and August. Of the eight workers with positive blood tests, four reported no symptoms. All eight cleaned milking parlors and none used respiratory protection such as face masks. Three said they used eye protection. 

High levels of the virus have been found in the milk of infected cows, increasing the risk of exposure and infection, researchers said. 

Researchers said that efforts to monitor dairy workers for illness have been hindered by several barriers including the reluctance of farm owners and farmworkers to allow testing. 

The virus has been confirmed in at least 446 cattle herds in 15 states. Last week, the Agriculture Department said a pig at an Oregon farm was confirmed to have bird flu, the first time the virus was detected in U.S. swine. 
…

KINSHASA, DEMOCRATIC REPUBLIC OF CONGO — The spread of mpox has slowed down slightly across Africa, but the epidemic is not over, the African Union’s health watchdog said Thursday.

Fifteen countries across Africa recorded 11,453 mpox cases in the last four weeks, compared with 12,802 in the four weeks prior, the Africa Centers for Disease Control and Prevention said during an online briefing.

But the head of the Africa CDC, Jean Kaseya, warned the epidemic was not over.

“We are still in the acute phase of the outbreak that is pushing us to double our effort to control mpox in Africa,” Kaseya said.

“Unfortunately, we are still losing a number of people,” he said.

Since the start of the year, authorities have recorded 50,840 mpox cases and 1,083 deaths across Africa.

Central Africa accounts for more than 85% of cases and almost all deaths.

The Democratic Republic of Congo, which has recorded more than 39,000 cases and more than 1,000 deaths since the start of the year, launched a vaccination campaign last month that is still “limited,” according to the Africa CDC.

Some 51,649 people have been vaccinated in six provinces, the Africa CDC said.

“We hope that with these vaccines we can continue to support countries to stop this outbreak,” Kaseya said.

Health agencies across the world have allocated just under 900,000 vaccine doses for nine African countries “hard hit by the current mpox surge,” the Africa CDC said in a statement Tuesday.

The countries include the DRC, Kenya and Uganda.

“The largest number of doses — 85% of the allocation — will go to the Democratic Republic of the Congo as the most affected country, reporting four out of every five laboratory confirmed cases in Africa this year,” the statement said.

Mpox, previously known as monkeypox, is caused by a virus transmitted to humans by infected animals but can also be passed from human to human through close physical contact.

It causes fever, muscular aches and large boil-like skin lesions, and can be deadly.
…

Washington — Researchers at Michigan State University recently discovered that honeybees, with their keen sense of smell, can sniff out lung cancer on a patient’s breath.

“Our world is visual. Insects’ world is all based on smell, so their sense of smell is very, very good,” says Debajit Saha, assistant professor of biomedical engineering at Michigan State University, who was part of a team that published research on the discovery last month.

“There is quite a bit of research that shows that when some cancer grows inside our body, our breath actually changes. Our research does show that honeybees can detect lung cancer and possibly other diseases based on the smell of those cells.”

Saha and his team harnessed the bees and attached electrodes to their brains. The insects were then exposed to synthetic compounds that mimicked the breath of a lung cancer patient. Ninety-three percent of the time, the bees could tell the difference between the cancer breath and the artificial breath of a healthy person. The bees could also distinguish between different types of lung cancer.

The discovery could have implications for early detection of many cancers, including lung, breast, head and neck, and colorectal cancers.

“We do think breath-based diagnostics of cancer can be a game changer,” Saha says. “The reason is, many times we detect the cancer late, when the tumor has already grown pretty big. But generally, when cancer starts growing in your body, the breath signature starts changing much earlier.”

He hopes to develop a portable system in which electrodes are implanted in a honeybee brain that a patient will be able to breathe into. This cyborg sensor, which is part-brain, part-engineered, would deliver test results in real time.

“Hopefully, within the next five years, we’ll have something to show that humans can be diagnosed using these insect brain disc sensors,” Saha says.

Using animals to detect cancer isn’t a new concept. At the Penn Vet Working Dog Center at the University of Pennsylvania, researchers are training dogs to recognize certain cancer odors.

“A lot of other animals also have quite intense and capable senses of smell,” says Cindy Otto, executive director of the Penn Vet Working Dog Center. “But part of what makes dogs so good is that they cooperate with humans, and so, they communicate that information.”

The dogs are in a foster program where they live with families and are brought to “work” each day. Not all dogs can do the work, according to Clara Wilson, a postdoctoral researcher at the center.

“If the dog is not really interested in this type of work, we find out pretty quickly. And you can’t make a dog want to do this, because they’re not going to give you high-quality answers,” Wilson says. “They need to love it to be engaged. And so, it’s a really fun game for them.”

Sniffing out cancer might be a game to the animals, but researchers are finding that the animals detect cancer better than machines. A dog’s sense of smell is 10,000 to 100,000 times more acute than that of humans.

“Why are we finding that these dogs are outperforming the computers?” says Amritha Mallikarjun, another postdoctoral researcher at the center. “Well, part of their success is because of this superior sensitivity to detect odor molecules as compared to anything we currently have on the market.”

The researchers hope to continue isolating characteristics of cancer odors to enhance technological development, eventually creating e-noses that duplicate a dog’s cancer sniffing abilities, enabling earlier detection of cancer.

“This may not be the endgame, but I think it’s going to advance the overall approach to diagnosing not only cancer but many other diseases,” Otto says.

“You can look back in history to the Greeks and Romans. The physicians then used odor as part of their diagnostic tools, and I think as modern humans, we’ve kind of let go of that. I think we can really capitalize on that and advance the health of not only humans, but dogs and other species as well.”
…

CHICAGO — For the second year in a row, Earth will almost certainly be the hottest it’s ever been. And for the first time, the globe this year reached more than 1.5 degrees Celsius of warming compared to the pre-industrial average, the European climate agency Copernicus said Thursday.

“It’s this relentless nature of the warming that I think is worrying,” said Carlo Buontempo, director of Copernicus.

Buontempo said the data clearly shows the planet would not see such a long sequence of record-breaking temperatures without the constant increase of greenhouse gases in the atmosphere driving global warming.

He cited other factors that contribute to exceptionally warm years like last year and this one. They include El Nino — the temporary warming of parts of the Pacific that changes weather worldwide — as well as volcanic eruptions that spew water vapor into the air and variations in energy from the sun. But he and other scientists say the long-term increase in temperatures beyond fluctuations like El Nino is a bad sign.

“A very strong El Nino event is a sneak peek into what the new normal will be about a decade from now,” said Zeke Hausfather, a research scientist with the nonprofit Berkeley Earth.

News of a likely second year of record heat comes a day after Republican Donald Trump, who has called climate change a “hoax” and promised to boost oil drilling and production, was reelected to the U.S. presidency. It also comes days before the next U.N. climate conference, called COP29, is set to begin in Azerbaijan. Talks are expected to focus on how to generate trillions of dollars to help the world transition to clean energies like wind and solar, and thus avoid continued warming.

Buontempo pointed out that going over the 1.5 degree Celsius threshold of warming for a single year is different than the goal adopted in the 2015 Paris Agreement. That goal was meant to try to cap warming at 1.5 degrees Celsius since pre-industrial times on average, over 20 or 30 years.

A United Nations report this year said that since the mid-1800s on average, the world has already heated up 1.3 degrees Celsius — up from previous estimates of 1.1 degrees or 1.2 degrees. That’s of concern because the U.N. says the greenhouse gas emission reduction goals of the world’s nations still aren’t nearly ambitious enough to keep the 1.5 degree Celsius target on track.

The target was chosen to try to stave off the worst effects of climate change on humanity, including extreme weather. “The heat waves, storm damage, and droughts that we are experiencing now are just the tip of the iceberg,” said Natalie Mahowald, chair of Earth and Atmospheric Sciences at Cornell University.

Going over that number in 2024 doesn’t mean the overall trend line of global warming has, but “in the absence of concerted action, it soon will,” said University of Pennsylvania climate scientist Michael Mann.

Stanford University climate scientist Rob Jackson put it in starker terms. “I think we have missed the 1.5 degree window,” said Jackson, who chairs the Global Carbon Project, a group of scientists who track countries’ carbon dioxide emissions. “There’s too much warming.”

Indiana state climatologist Beth Hall said she isn’t surprised by the latest report from Copernicus, but emphasized that people should remember climate is a global issue beyond their local experiences with changing weather. “We tend to be siloed in our own individual world,” she said. Reports like this one “are taking into account lots and lots of locations that aren’t in our backyard.”

Buontempo stressed the importance of global observations, bolstered by international cooperation, that allow scientists to have confidence in the new report’s finding: Copernicus gets its results from billions of measurements from satellites, ships, aircraft and weather stations around the world.

He said that going over the 1.5 degree Celsius benchmark this year is “psychologically important” as nations make decisions internally and approach negotiations at the annual U.N. climate change summit Nov. 11-22 in Azerbaijan.

“The decision, clearly, is ours. It’s of each and every one of us. And it’s the decision of our society and our policymakers as a consequence of that,” he said. “But I believe these decisions are better made if they are based on evidence and facts.”
…

An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations said on Wednesday.

The WHO declared mpox a global public health emergency for the second time in two years in August after a new variant of the virus, called clade Ib, spread from the Democratic Republic of Congo to neighboring countries.

In September, after facing criticism on moving too slowly on vaccines, the World Health Organization cleared Bavarian Nordic’s BAVA.CO vaccine for mpox and said it was considering LC16, made by Japan’s KM Biologics as a potential vaccine option.

The WHO also set up a scheme to help bring mpox vaccines, tests and treatments to the most vulnerable people in the world’s poorest countries, similar to efforts during the COVID-19 pandemic.

The global health agency said on Wednesday the newly allocated vaccines will go to the Central African Republic, Ivory Coast, the Democratic Republic of Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa and Uganda.

The largest number of doses – 85% of the allocated vaccines – will go to the Democratic Republic of Congo as the most affected country, the WHO said.

The allocated vaccines are from European countries, the United States, Canada and Gavi, a public-private alliance that co-funds vaccine purchases for low-income countries.

According to the latest WHO figures, there have been more than 46,000 confirmed and suspected cases of mpox in Africa this year, and more than 1,000 deaths in the continent due to the viral illness.
…

In labs across the United States, scientists are working on innovative tests using animals and insects to detect cancer earlier. As VOA’s Dora Mekouar reports, recent research suggests bees and dogs can sniff out the disease sooner than machines can.
…

London — Two new cases of the mpox variant clade 1b detected in the U.K. are the first locally transmitted cases in Europe and the first outside Africa, the World Health Organization said Tuesday.

The U.K. Health Security Agency (UKHSA) confirmed late Monday that the two new cases were household contacts of Britain’s first case identified last week, bringing the country’s total confirmed cases to three.

The WHO warned that European states should be prepared for “rapid action” to contain the latest mpox variant, which spreads through close physical contact including sexual relations and sharing closed spaces.

The two cases are also the first to be locally transmitted outside Africa since August 2024, when the WHO declared the outbreak of the new variant an international public health emergency — its highest level of alarm.

Those affected are under specialist care and the risk to the U.K. population “remains low,” UKHSA said.

The original case was detected after the person traveled to several African countries on holiday and returned to the U.K. on Oct. 21.

The patient developed flu-like symptoms more than 24 hours later and, on Oct. 24, started to develop a rash that worsened in the following days.

Mpox, a viral disease related to smallpox, has two types, clade 1 and clade 2. Symptoms include fever, a skin rash or pus-filled blisters, swollen lymph nodes and body aches.

The WHO first declared an international public health emergency in 2022 over the spread of clade 2. That outbreak mostly affected gay and bisexual men in Europe and the United States.

Vaccination and awareness drives in many countries helped stem the number of worldwide cases and the WHO lifted the emergency in May 2023 after reporting 140 deaths out of around 87,400 cases.

In 2024, a two-pronged epidemic of clade 1 and clade 1b, a new strain that affects children, has spread widely in the Democratic Republic of Congo.

The new strain has also been recorded in neighboring Burundi, Kenya, Rwanda and Uganda, with imported cases in Sweden, India, Thailand, Germany and the U.K.
…

Geneva — The World Health Organization on Tuesday listed 17 pathogens that cause widespread disease and death, including HIV, malaria and tuberculosis, for which it said new vaccines were “urgently needed.”

The U.N. health agency said that it with its list was providing the first global effort to systematically prioritize endemic pathogens based on criteria including disease burdens, antimicrobial resistance risk and the socioeconomic impact.

“We need to do this because we would like to shift the focus from developing vaccines away from commercial returns towards regional and global health needs,” Mateusz Hasso-Agopsowicz, a WHO vaccine specialist, told reporters in Geneva via video link from Poland.

The study reconfirms longstanding priorities for vaccine research and development, including HIV, malaria and tuberculosis — three diseases that collectively kill nearly 2.5 million people each year, WHO said.

But it also identifies lesser-known pathogens as top disease control priorities, highlighting the urgency to develop new vaccines for pathogens that are becoming increasingly resistant to antimicrobials.

Among them was Group A streptococcus, which causes severe infections and contributes to some 280,000 deaths from rheumatic heart disease each year, mainly in lower-income countries.

Ita also highlights the dangers of Klebsiella pneumoniae — a bacterium that is responsible for around 40% of neonatal deaths due to blood infection, or sepsis, in low-income countries.

These vaccines “would not only significantly reduce diseases that greatly impact communities today but also reduce the medical costs that families and health systems face,” WHO vaccine chief Kate O’Brien said in a statement.

Vaccines for the various pathogens listed are at different stages of development, WHO said, with some like ones for HIV, Group A streptococcus and hepatitis C virus still at the research stage. 

Others, like ones for dengue and tuberculosis, have been developed and are approaching regulatory approval or introduction.

Hasso-Agopsowicz explained that the 17 listed pathogens were wreaking the most havoc in lower-income countries, explaining why more progress has not been made previously on developing vaccines against them.

“What typically has happened in the past is that vaccine research and development has been influenced by profitability of new vaccines. What that means is that diseases that severely affect low-income regions unfortunately receive much less attention,” he said.

With the new list, he said, “we want to change the focus… so that the new vaccine research and development is driven by health burden and not just commercial opportunities.”
…

geneva — World Health Organization member countries resumed negotiations Monday to finalize an agreement on pandemic prevention, with outbreaks of mpox, Marburg and H5N1 stressing the urgency of reaching an agreement without repeating the deadly mistakes of COVID-19.

After more than two years of negotiations, there is hope of reaching an agreement in the next 15 days, especially since the negotiators have agreed to postpone discussions on the most contentious points: the sharing of knowledge and equitable access to medical advances.

Recent negotiations at COP16 in Colombia on biodiversity, which provided for a comparable mechanism, stumbled on this point.

WHO chief Tedros Adhanom Ghebreyesus stressed the need to balance timeliness and workable deal.

“Time is not our friend,” Tedros told national negotiators at the opening of the talks. “COVID is still circulating. Mpox is a global health emergency. We have a Marburg outbreak and H5N1 spreading. The next pandemic will not wait.”

Never again

In December 2021, fearing a repeat of the catastrophe caused by COVID-19, which killed millions of people, the 194 member countries of WHO agreed to reach an agreement on pandemic prevention, preparedness and response.

The emergence of a new strain of mpox, the deadly Marburg virus outbreak in Rwanda and the spread of H5N1 avian flu in recent months have clarified the issues.

Diplomats have agreed on most of the draft’s 37 articles during 11 rounds of negotiations.

The main section on which consensus will need to be found concerns access to pathogens for the scientific community and medical research, and then to products to combat the pandemic such as vaccines or other tests derived from this research.

In order not to block everything, the idea is to postpone the discussion on the details of the pathogen access and benefit sharing system (PABS) until later.

Battle for fairness

For the moment, there is an impasse between rich and poor countries, which have not forgotten that they were abandoned to their fate during the COVID-19 pandemic.

“If the world has failed on one thing, it is on the issue of equity” during the COVID-19 pandemic, the head of WHO stressed on Friday.

“Africa was left behind at the time, and this should not happen,” Tedros said.

‘Bitter taste’

Helen Clark, former New Zealand Prime Minister, believes that “the South sees the North as protecting its pharmaceutical industries,” and this “has left an incredibly bitter taste between the North and the South.”

The International Federation of Pharmaceutical Manufacturers and Associations called for an agreement “allowing the private sector to innovate.”

“Intellectual property must be respected, and technology transfer must always be voluntary and on mutually agreed terms,” the federation insisted.

Among the country representatives, Malaysia, speaking on behalf of a group of developing countries known as the Equity Group, said “major improvements are still desperately needed in many areas.”

It demanded that at least 20% of real-time production of vaccines, tests and treatments go to developing countries.

Tanzania, on behalf of 48 African countries, said it could not “accept an agreement not based on equity.”

The Indonesian negotiator said an agreement that only preserves the status quo is unacceptable, because “empty promises will not save lives.”

China insisted that “quality should not be sacrificed for time.”

Germany’s representative called for an acceleration of the talks to “focus on what is achievable.”
…

CALI, Colombia — Wealthy nations appeared to hit a limit with how much they are willing to pay to conserve nature around the world, instead shifting their focus at the two-week U.N. biodiversity summit toward discussions of private money filling the funding gap.

At the COP16 negotiations in Cali, Colombia, countries failed to figure out how they would mobilize $200 billion annually in conservation funding by 2030, including $30 billion that would come directly from rich nations.

That money, pledged two years ago as part of the landmark Kunming-Montreal Global Biodiversity Framework agreement, is meant to finance activities that boost nature, such as sustainable farming or patrolling wildlife reserves.

But there was no consensus as talks dragged on beyond the summit’s scheduled end on Friday, during which dozens of delegations departed. By Saturday morning’s roll call, there was no longer a quorum among the nearly 200 nations for an agreement to pass, forcing organizers to abruptly suspend the meeting.

“I am both saddened and enraged by the non-outcome of COP16,” said Shilps Gautam, chief executive of project finance firm Opna.

“The wild thing about the nature financing discussions is that the numbers discussed are already a pittance.”

Human activities such as farming, mining, and urban development are increasingly pushing nature into crisis, with 1 million or so plant and animal species thought to be at risk of extinction.

Climate change, a result of fossil fuel burning, is also adding to nature’s woes by raising temperatures and disrupting weather cycles.

Countries will meet again in Azerbaijan next week for the U.N.’s COP29 climate summit, which again will be focused on the steep need for funding from wealthy nations to their poorer counterparts to help shoulder climate costs.

Little money from rich nations

Even before the talks broke down, developed nations had signaled an unwillingness to offer large amounts of cash.

European governments including Germany and the Netherlands have slashed their foreign aid budgets over the last year, while France and the U.K. are also cutting back.

Government development money specifically targeted at nature conservation abroad fell to $3.8 billion in 2022 compared with $4.6 billion in 2015, according to the Organization for Economic Co-operation and Development.

At COP16, U.N. Secretary General Antonio Guterres demanded that countries make significant new contributions to the Global Biodiversity Framework Fund.

The response was muted. Nations at COP16 pledged $163 million in contributions to the fund, bringing total contributions to roughly $400 million – far from a major contribution to the $30 billion target from nations by 2030.

The United States, which is not a party to U.N. Convention on Biological Diversity, has not contributed.

“The public money is already leveraged as much as we can,” Florika Fink-Hooijer, the European Union’s director general of environment, told reporters at the summit.

“We now have to look at other sources of funding.”

Private cash

When it came to going after private capital, delegates at the COP16 summit agreed to a plan to charge pharmaceutical and other companies for their use of genetic information in the research and development of new commercial products.

Pharmaceutical companies Pfizer, Merck, AstraZeneca and Land Sanofi did not respond to request for comment on the deal.

Experts estimate the plan could generate about $1 billion annually.

That still doesn’t cover the billions needed to halt the collapse of ecosystems, like the Amazon rainforest or coral reefs. The world will need to devise ways for enticing private investment in nature-friendly projects, said Marcos Neto, director of global policy at the U.N. Development Program.

Some tools include green bonds or debt-for-nature swaps, whereby countries refinance their debt at lower interest rates in order to spend the savings on conservation. The World Economic Forum estimates that debt-for-nature swaps could generate $100 billion in nature funding.
…

Goma, Congo — Some health officials say mpox cases in Congo appear to be “stabilizing” — a possible sign that the main epidemic for which the World Health Organization made a global emergency declaration in August might be on the decline.  

In recent weeks, Congo has reported about 200 to 300 lab-confirmed mpox cases every week, according to WHO. That’s down from nearly 400 cases a week in July. The decline is also apparent in Kamituga, the mining city in the eastern part of Congo where the new, more infectious variant of mpox first emerged.  

But the U.N. health agency acknowledged Friday that only 40% to 50% of suspected infections in Congo were being tested — and that the virus is continuing to spread in some parts of the country and elsewhere, including Uganda.  

While doctors are encouraged by the drop in infections in some parts of Congo, it’s still not clear what kinds of physical contact is driving the outbreak. Health experts are also frustrated by the low number of vaccine doses the central African nation has received — 265,000 — and say that delivering the vaccine to where it’s needed in the sprawling country is proving difficult. WHO estimates 50,000 people have been immunized in Congo, which has a population of 110 million.  

Scientists also say there needs to be an urgent, broader vaccination effort for the entire continent to halt mpox’s spread and avoid further worrisome genetic mutations, like the one detected earlier this year in Congo after months of low-level circulation.  

“If we miss this opportunity, the likelihood of another significant outbreak increases substantially,” said Dr. Zakary Rhissa, who heads operations in Congo for the charity Alima.  

So far this year, there have been roughly 43,000 suspected cases in Africa and more than 1,000 people have died, mostly in Congo.  

“We’ve seen how past outbreaks, such as the one in Nigeria in 2017, can lead to larger global events if not effectively contained,” he said. The 2017 epidemic ended up leading to the 2022 global outbreak of mpox that affected more than 100 countries.  

Rhissa said the decline in cases in Kamituga — where mpox initially spread among sex workers and miners — is an opening to put more programs in place for vaccination, surveillance and education.  

Georgette Hamuli, an 18-year-old sex worker, hadn’t been aware of mpox until immunization teams arrived last week in the poor neighborhood where she works in Goma, the biggest city in eastern Congo.  

“They told us we’re highly exposed to the risk of infection,” she said. “We insist on condoms with our clients, but some refuse … if they don’t want to use a condom, they double the amount they pay.”  

Hamuli said she and other friends who are sex workers each received 2,000 Congolese francs ($0.70) from a charity to get vaccinated against mpox — but it wasn’t the money that swayed her. 

“The vaccine is also necessary,” she said. “I think we’re now protected.”   

The Africa Centers for Disease Control and Prevention has estimated Congo needs at least 3 million mpox vaccines to stop the virus, and another 7 million for the rest of Africa. So far, WHO and partners have allocated 900,000 vaccines to nine African countries affected by mpox and expect 6 million vaccines to be available by the end of this year.  

Mpox epidemics in Burundi, Kenya, Rwanda and Uganda had their origins in Congo, and a number of cases in travelers have also been identified in Sweden, Thailand, Germany, India and Britain.  

Fewer than half of the people who are most at risk in Congo have been vaccinated, according to Heather Kerr, Congo director for the International Rescue Committee.  

“We only have a tiny amount of vaccines, and nothing for the kids,” she said.  

The vaccines for Congo are largely coming from donor countries like the U.S and through UNICEF, which mainly uses taxpayer money to buy the shots.  

“We’re getting a charitable approach where we only see very small donations of vaccines to Africa,” said Dr. Chris Beyrer, director of the Global Health Institute at Duke University. “What we need is a public health approach where we immunize populations at scale.”  

Drugmaker Bavarian Nordic, which makes the most widely used mpox vaccine, said it would sell shots destined for Africa at the lowest price possible.  

The advocacy group Public Citizen estimated UNICEF paid $65 per dose of the Jynneos mpox vaccine made by Bavarian Nordic, far higher than nearly all other vaccines used in public health programs. 

Dr. Salim Abdool Karim, an infectious diseases expert at South Africa’s University of KwaZulu-Natal, said mpox outbreaks typically peak and disappear quickly because of how the virus spreads. This time, however, he said there are two complicating factors: the virus’ transmission via sex and the continued spillover from infected animals.  

“We’re in new territory with mpox this time,” he added. “But we’re never going to solve this until we vaccinate most of our people.” 
…